Ulipristal - HRA Pharma
Alternative Names: CDB-2914; ella; ellaOne; Esmya; Fibristal; HRP 2000; PGL-4001; RTI 3021-12; RU 44675; Ulipristal acetate; UPA; UPA C-IUS; UPA C-ring; UPA-IUS; UPA-UF; UPA-VR; VA-2914Latest Information Update: 06 May 2022
At a glance
- Originator HRA Pharma; National Institutes of Health (USA)
- Developer AbbVie; ASKA Pharmaceutical; Gedeon Richter; HRA Pharma; Population Council (USA); PregLem
- Class Antineoplastics; Norpregnadienes; Oral contraceptives; Small molecules
- Mechanism of Action Selective progesterone receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Female genital diseases; Uterine leiomyoma
Highest Development Phases
- Marketed Pregnancy; Uterine leiomyoma
- Discontinued Breast cancer; Endometriosis; Menopausal syndrome
Most Recent Events
- 02 May 2022 HRA Pharma has been acquired by Perrigo
- 15 Jan 2021 The European Commission (EC) restricted the use of ulipristal acetate for the Uterine leiomyoma in the European Union followed by the CHMP opinion
- 04 Sep 2020 EMA’s safety committee (PRAC) has recommended revocation of marketing authorisation of Ulipristal for the treatment of uterine leiomyoma